学生团队

当前位置: 首页 > 学生团队 > 在校生情况 > 正文

2023级药学研究生—吕鑫亚

发布日期:2026-05-18 作者: 阅读:

3dbb9854d268169ba834c1f8c4be0a7d

教育背景:

2019.9-2023.7,江西科技师范大学,药物制剂,理学学士

2023.9-2026.7,江西科技师范大学,药学,理学硕士

在校成果:

[1] Lv X, Liu C, Liu L, et al. Electrophotochemical Anti-Markovnikov Selective Carboxylation of Alkenes [J]. J Org Chem, 2026, 91(4): 1745–52.(第一作者)

[2] Lv X, Huang X, Tian L, et al. CADD-Based Discovery of Novel Heterocyclic Pyrimidine-Based CDK4/6 Inhibitors: Design, Synthesis, and Anti-Breast Cancer Activity Studies [J]. Eur. J. Med. Chem., 2026.(第一作者)

[3] Lv X, Fan L, Zhan Y, et al. A Paradigm Shift in Drug Discovery: PROTAC Systematic Design, Emerging Strategies and Applications in Tumor Therapy. [J]. Arch. Pharm. Res.(第一作者,under review

[4] Lv X, Fan L, Xu S, et al. Design, Synthesis and Application of PROTACs for c-Met Degradation Based on CADD Strategy in Cancer. [J].Eur. J. Med. Chem., 2026.(第一作者,under review

[5] An Y, Lv X, Xu S, et al. Pyrimidine-based dual-target inhibitors targeting epidermal growth factor receptor for overcoming drug resistance in cancer therapy(2006-present)[J]. Eur. J. Med. Chem. 2025, 286, 117268.(第二作者)

[6] Huang X, Xu S, An Y, Lv X, et al. Revealing 5-(3, 5-difluorobenzyl)-1H-indazole as the active pharmacophore of ALK/ROS1 dual inhibitors through theoretical calculations and biological activity evaluations[J]. Bioorg. Chem., 2025, 154, 108014.(第四作者)

[7] Wang L, Huang X, Xu S, An Y, X. Lv, et al. Fused in silico and bioactivity evaluation method for drug discovery: T001-10027877 was identified as an antiproliferative agent that targets EGFRT790M/C797S/L858R and EGFRT790M/L858R[J]. BMC Chem., 2024, 18, 159.(第五作者)

[8] Xu S, Huang X, An Y, Lv X, et al. In silico screening applied indrug discovery: T001-10026247 as a novel fourth-generati on EGFR inhibitor[J]. New J. Chem. 2023, 47, 20405.

[9] 陈淑慧,钟晓鸣,吕巧莉,吕鑫亚,黄小玲等,一种含杂环嘧啶类化合物及其应用,CN120424049A

[10] 陈淑慧,安宇凤,吕鑫亚,钟晓鸣,郑鹏武等,一种靶向EGFRAXL靶点的4-氨基嘧啶类化合物及其制备方法和应用,CN120647626A

[11] 徐珊,夏露露,乔丹,张红,吕鑫亚等,一种含嘧啶结构的酰胺类化合物及其在制备TYK2 JH2激酶抑制剂中的应用,CN120607493A

荣誉奖励

2025年中国国际大学生创新大赛国家级银奖1项;

2024年获中国国际大学生创新大赛省级铜奖3项;

2024年获挑战杯创新创业大赛省级铜奖1项;

2023年全国大学生药苑论坛优秀成果三等奖2项;

2023年江西省互联网+创新创业大赛省级银奖2项;

2023年江西省互联网+创新创业大赛省级铜奖1项;

2023-2024学年江西省学业奖学金;

2024-2025学年江西省学业奖学金;

2025-2026学年江西省学业奖学金。

联系方式:lvxinya7@163.com13105258146


江西省药物分子设计与评价重点实验室 第一实验楼

电话:0791-83802393

地址:江西南昌昌北经济技术开发区枫林西大街605号

版权所有:药物分子设计与评价江西省重点实验室